Rossmore Private Capital Boosts Stock Position in Eli Lilly and Company (NYSE:LLY)

Rossmore Private Capital raised its holdings in Eli Lilly and Company (NYSE:LLY) by 0.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,148 shares of the company’s stock after acquiring an additional 34 shares during the period. Eli Lilly and Company comprises about 2.1% of Rossmore Private Capital’s investment portfolio, making the stock its 9th largest holding. Rossmore Private Capital’s holdings in Eli Lilly and Company were worth $16,964,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Simmons Bank boosted its stake in Eli Lilly and Company by 1.5% in the 3rd quarter. Simmons Bank now owns 8,409 shares of the company’s stock worth $7,450,000 after purchasing an additional 121 shares during the period. Haverford Trust Co lifted its holdings in shares of Eli Lilly and Company by 0.9% in the third quarter. Haverford Trust Co now owns 3,515 shares of the company’s stock valued at $3,114,000 after purchasing an additional 31 shares in the last quarter. Empower Advisory Group LLC boosted its position in shares of Eli Lilly and Company by 4.3% during the third quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock worth $123,388,000 after buying an additional 5,682 shares during the period. Moser Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 40.0% during the third quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock worth $403,000 after buying an additional 130 shares in the last quarter. Finally, Carrera Capital Advisors acquired a new stake in Eli Lilly and Company in the 3rd quarter valued at approximately $244,000. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the subject of several research reports. Truist Financial raised their price target on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Barclays cut their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price on the stock. Citigroup raised their price target on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Four research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,008.41.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the sale, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 1.6 %

Eli Lilly and Company stock opened at $818.79 on Wednesday. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53. The company’s 50-day moving average price is $891.02 and its two-hundred day moving average price is $870.71. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The stock has a market cap of $777.29 billion, a P/E ratio of 88.52, a P/E/G ratio of 3.15 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s quarterly revenue was up 20.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. As a group, analysts expect that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Friday, November 15th. Eli Lilly and Company’s dividend payout ratio is currently 56.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.